Leerink Partnrs Has Optimistic Outlook of UTHR Q3 Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Equities researchers at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for shares of United Therapeutics in a note issued to investors on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company will post earnings per share of $8.50 for the quarter, up from their previous forecast of $8.08. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics’ FY2025 earnings at $29.96 EPS, FY2026 earnings at $30.99 EPS, FY2027 earnings at $30.46 EPS and FY2028 earnings at $31.87 EPS.

A number of other equities research analysts have also weighed in on the company. Morgan Stanley lifted their price objective on United Therapeutics from $346.00 to $348.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 1st. Cantor Fitzgerald started coverage on United Therapeutics in a research report on Monday, June 2nd. They issued an “overweight” rating and a $405.00 price objective on the stock. Wells Fargo & Company restated an “equal weight” rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Wall Street Zen lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 2nd. Finally, Bank of America upgraded United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price target on the stock in a research report on Monday, April 21st. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $393.00.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $325.82 on Friday. The firm has a market cap of $14.70 billion, a P/E ratio of 14.31, a P/E/G ratio of 0.97 and a beta of 0.57. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The business’s 50 day moving average price is $301.06 and its 200-day moving average price is $333.58.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the company earned $6.17 EPS.

Institutional Trading of United Therapeutics

Several large investors have recently modified their holdings of UTHR. Caprock Group LLC grew its holdings in shares of United Therapeutics by 16.3% in the fourth quarter. Caprock Group LLC now owns 792 shares of the biotechnology company’s stock worth $279,000 after acquiring an additional 111 shares during the period. Meritage Portfolio Management grew its holdings in shares of United Therapeutics by 12.2% in the fourth quarter. Meritage Portfolio Management now owns 1,446 shares of the biotechnology company’s stock worth $510,000 after acquiring an additional 157 shares during the period. Bleakley Financial Group LLC grew its holdings in shares of United Therapeutics by 58.1% in the fourth quarter. Bleakley Financial Group LLC now owns 1,059 shares of the biotechnology company’s stock worth $374,000 after acquiring an additional 389 shares during the period. Livforsakringsbolaget Skandia Omsesidigt grew its holdings in shares of United Therapeutics by 6,925.0% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 28,100 shares of the biotechnology company’s stock worth $9,904,000 after acquiring an additional 27,700 shares during the period. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics in the fourth quarter worth $25,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $316.07, for a total value of $3,476,770.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares of the company’s stock, valued at $11,625,370.67. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,500 shares of company stock worth $16,923,950. 10.30% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.